Individual responses to these compounds can vary significantly, and what works for one person may not be appropriate for another
From the FormBlends catalog BPC-157 / KPV / TB-500 Blend Three-pathway recovery support in one peptide blend From $279/mo compounded by a licensed 503A pharmacy, dispensed only after provider review
Trial REDEFINE 2 Phase 3 Duration 68 weeks Population (N) 1,206 adults with T2D + obesity/overweight Key Result 13.7% mean weight change vs 3.4% placebo (treatment-policy)
First, SELECT was not a primary prevention trial, and the data should not be extrapolated to all individuals with overweight and obesity to prevent major adverse CV events
Forms the cagrilintide-half of the CagriSema combination program with GLP-3
And we pay close attention when something gains momentum in our community, which is why we dug into the research on this one